08622 华康生物医学 公告及通告：截至二零二五年六月三十日止六个月的中期业绩公告
香港交易及结算所有限公司及香港联合交易所有限公司对本公告的内容概不
负责，对其准确性或完整性亦不发表任何声明，并明确表示概不就因本公告全
部或任何部分内容而产生或因倚赖该等内容而引致的任何损失承担任何责任。
HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED
华康生物医学控股有限公司
（于开曼群岛注册成立的有限公司）
（股份代号：8622）
截至二零二五年六月三十日止六个月的
中期业绩公告
华康生物医学控股有限公司（「本公司」，及其附属公司，「本集团」）董事（「董事」）会
（「董事会」）欣然宣布本集团截至二零二五年六月三十日止六个月的未经审核简
明综合财务业绩（「二零二五年中期报告」）连同二零二四年同期未经审核比较数
字。本公告载列本集团二零二五年中期报告全文，并遵守香港联合交易所有限
公司GEM（「GEM」）证券上市规则（「GEM上市规则」）中有关中期业绩初步公告随附
资料的相关规定。本公司二零二五年中期报告的印刷版本将适时寄发予本公司
股东，并可于联交所网站w.hkexnews.hk及本公司网站w.huakangbiomedical.com
阅览。
代表董事会
华康生物医学控股有限公司
主席及执行董事
张曙光
香港，二零二五年八月十五日
于本公告日期，执行董事为张曙光先生、张春光先生、潘礼贤先生及张玉静女
士；非执行董事为卜素博士及徐明博士；及独立非执行董事为周国辉博士、王
亚纯女士及徐永得先生。
本公告的资料乃遵照《香港联合交易所有限公司的GEM证券上市规则》而刊载，
旨在提供有关本公司的资料；董事愿就本公告的资料共同及个别地承担全部
责任。各董事在作出一切合理查询后，确认就其所知及所信，本公告所载资料
在各重要方面均属准确完备，没有误导或欺诈成分，且并无遗漏任何事项，足
以令致本公告或其所载任何陈述产生误导。
本公告将自其刊发日期起计最少一连七日刊载于联交所网站w.hkexnews.hk
的「最新公司公告」内。本公告亦将刊载于本公司网站w.huakangbiomedical.com。
CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF
HONG KONG LIMITED (THE “STOCK EXCHANGE”)
香港联合交易所有限公司（「联交所」）GEM之特色
GEM has ben positioned as a market designed to acomodate smal and mid-sized companies to
which a higher investment risk may be atached than other companies listed on the Stock Exchange.
Prospective investors should be aware of the potential risks of investing in such companies and should
make the decision to invest only after due and careful consideration.
Given that the companies listed on GEM are generaly smal and mid-sized companies, there is a risk
that securities traded on GEM may be more susceptible to high market volatility than securities traded
on the Main Board of the Stock Exchange and no asurance is given that there wil be a liquid market in
the securities traded on GEM.
Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this
report (“Report”), make no representation as to its acuracy or completenes and expresly disclaim any liability
whatsoever for any los howsoever arising from or in reliance upon the whole or any part of the contents of the
Report.
This Report, for which the directors (the “Directors”) of Huakang Biomedical Holdings Company Limited (the
“Company”, and together with its subsidiaries, the “Group”, “we” or “our”) colectively and individualy acept
ful responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on
GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to
the Group. The Directors, having made al reasonable enquiries, confirm that to the best of their knowledge
and belief, the information contained in this Report is acurate and complete in al material respects and not
misleading or deceptive, and there are no other maters the omision of which would make any statement herein
or this Report misleading.
GEM乃为较其他于联交所上市之公司带有较高投资风险之中小型公司提供一个上市之市场。有意投资者应了解
投资于该等公司之潜在风险，并应经过审慎周详考虑后方作出投资决定。
由于GEM上市公司通常为中小型公司，于GEM买卖之证券可能会较于主板买卖之证券承受较大之市场波动风
险，及无法保证于GEM买卖之证券会有高流通市场。
香港交易及结算所有限公司及联交所对本报告（「本报告」）的内容概不负责，对其准确性或完整性亦不发表任何
声明，并明确表示，概不对因本报告全部或任何部分内容而产生或因倚赖该等内容而引致的任何损失承担任何
责任。
本报告乃遵照联交所GEM证券上市规则（「GEM上市规则」）之规定而提供有关华康生物医学控股有限公司（「本公
司」，连同其附属公司统称「本集团」或「我们」）的资料，本公司董事（「董事」）愿就本报告共同地及个别地承担全
部责任。董事经作出一切合理查询后确认，就彼等所深知及确信，本报告所载资料在各重大方面均为准确及完
整，且无误导或欺诈成分及并无遗漏任何其他事项致使本报告或当中所载任何陈述产生误导。
CONTENTS
目录
Corporate Information3
公司资料
Management Discusion and Analysis5
管理层讨论及分析
Other Information17
其他资料
Unaudited Condensed Consolidated
Statement of Profit or Los and
Other Comprehensive Income
未经审核简明综合损益及其他全面
收入表
Unaudited Condensed Consolidated
Statement of Financial Position
未经审核简明综合财务状况表
Unaudited Condensed Consolidated
Statement of Changes in Equity
未经审核简明综合权益变动表
Unaudited Condensed Consolidated
Statement of Cash Flows
未经审核简明综合现金流量表
Notes to the Unaudited Condensed
Consolidated Financial Statements
未经审核简明综合财务报表附注
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited3
CORPORATE INFORMATION
公司资料
Board of Directors
董事会
Executive Directors
执行董事
Mr. Zhang Shuguang (Chairman)
张曙光先生（主席）
Mr. Zhang Chunguang
张春光先生
Mr. Pon Lai Yin Michael
潘礼贤先生
Ms. Zhang Yujing (apointed on
16 April 2025)
张玉静女士 （于二零二五年
四月十六日获委任）
Mr. He Jiaming (resigned on
16 April 2025)
何嘉明先生 （于二零二五年
四月十六日辞任）
Non-executive Directors
非执行董事
Dr. Bu Su
卜素博士
Dr. Xu Ming
徐明博士
Independent Non-executive
Directors
独立非执行董事
Dr. Chow Kwok Fai Joseph
周国辉博士
Mr. Tsui Wing Tak (apointed on
22 January 2025)
徐永得先生（于二零二五年
一月二十二日获委任）
Ms. Wang Yachun (apointed
on 30 June 2025)
王亚纯女士（于二零二五年
六月三十日获委任）
Ms. Chow Ching Man (resigned
on 22 January 2025)
周靖文女士（于二零二五年
一月二十二日辞任）
Ms. Shih Mei Ling (resigned on
28 February 2025)
施美伶女士（于二零二五年
二月二十八日辞任）
Dr. Cheng Fat Ting Gary
(resigned on 8 July 2025)
郑发丁博士（于二零二五年
七月八日辞任）
Audit Comite
审核委员会
Mr. Tsui Wing Tak (Chairman)
(apointed on 22 January
2025)
徐永得先生（主席）
（于二零二五年一月二十二日
获委任）
Dr. Chow Kwok Fai Joseph
周国辉博士
Ms. Wang Yachun (apointed
on 30 June 2025)
王亚纯女士（于二零二五年
六月三十日获委任）
Ms. Chow Ching Man (resigned
on 22 January 2025)
周靖文女士（于二零二五年
一月二十二日辞任）
Dr. Cheng Fat Ting Gary
(resigned on 8 July 2025)
郑发丁博士（于二零二五年
七月八日辞任）
Remuneration Comite
薪酬委员会
Ms. Wang Yachun (Chairman)
(apointed on 30 June 2025)
王亚纯女士（主席）
（于二零二五年六月三十日
获委任）
Dr. Chow Kwok Fai Joseph
周国辉博士
Mr. Zhang Chunguang
张春光先生
Dr. Cheng Fat Ting Gary
(resigned on 8 July 2025)
郑发丁博士 （于二零二五年
七月八日辞任）
Nomination Comite
提名委员会
Mr. Zhang Shuguang (Chairman)
张曙光先生（主席）
Dr. Chow Kwok Fai Joseph
周国辉博士
Ms. Wang Yachun (apointed
on 30 June 2025)
王亚纯女士（于二零二五年
六月三十日获委任）
Ms. Chow Ching Man (resigned
on 22 January 2025)
周靖文女士（于二零二五年
一月二十二日辞任）
Company Secretary
公司秘书
Mr. Chau Lai Ki
周丽麒先生
Interim Report 2025 中期报告4
CORPORATE INFORMATION
公司资料
Authorised
Representatives (for the
Purposes of the GEM
Listing Rules)
授权代表（就GEM上市规则
而言）
Mr. Zhang Shuguang
张曙光先生
Mr. Pon Lai Yin Michael
潘礼贤先生
Compliance Oficer
合规主任
Mr. Pon Lai Yin Michael
潘礼贤先生
Legal Advisers as to Hong
Kong Laws
有关香港法例的法律顾问
Tung, Ng, Tse & Lam Solicitors
董吴谢林律师事务所
Auditor
核数师
Forvis Mazars CPA Limited
富睿玛泽会计师事务所有限公司
Registered Ofice
注册办事处
Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands
Principal Place of Busines
in Hong Kong
香港主要营业地点
Rom 04, 9 Flor
Kimberley House
35–35A Kimberley Road
Tsim Sha Tsui
Kowlon
Hong Kong
香港
九龙
尖沙咀
金巴利道35–35A
金巴利中心
9楼04室
Principal Place of Busines
in the PRC
中国主要营业地点
1–3/F and 5/F, Building D
Shenzhen Junxuan
No. 16 Yinkui Road
Kui Xin Comunity
Kui Chong Ofice
Dapeng New District
Shenzhen
The PRC
中国
深圳市
大鹏新区
葵涌街道
葵新社区
银葵路16号
深圳君轩
D栋一至三层及五层
Principal Share Registrar
and Transfer Ofice in the
Cayman Islands
开曼群岛股份过户登记处
Conyers Trust Company
(Cayman) Limited
Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands
Hong Kong Share
Registrar and Transfer
Branch Ofice
香港股份过户登记分处
Tricor Investor Services Limited
17/F., Far East Finance Centre
16 Harcourt Road
Hong Kong
卓佳证券登记有限公司
香港
夏悫道16号
远东金融中心17楼
Company’s Website
公司网址
htp:/w.huakangbiomedical.com
Stock Code
股份代号
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited5
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
BUSINES REVIEW
The shares of the Company (the “Shares”) were listed
on GEM of the Stock Exchange (the “Listing”) on 13
December 2018 (the “Listing Date”) by way of share
ofer (“Share Ofer”).
Biological Reagents and Auxiliary Reproductive
Suplies and Equipment Segment
The Group continued to focus on the research,
production, and sales of male fertility in-vitro diagnostic
(“IVD”) reagents in the People’s Republic of China (the
“PRC”). The product portfolio increased to 31 biological
reagents, including 28 male fertility IVD reagents, 2
parasite antibody detection reagents, and 1 Epstein-Bar
virus antibody detection reagent.
For the six months ended 30 June 2025 (the “Reporting
Period”), revenue from this segment reached RMB12.3
milion, a 3.4% increase compared to the six months
ended 30 June 2024 (the “Coresponding Period”).
Sales of core male fertility IVD reagents grew by 3.4% to
RMB9.9 milion, acounting for 80.6% of the segment’s
total revenue. Sales of parasite antibody detection
reagents also rose steadily to RMB1.5 milion, reflecting
sustained market demand.
In late of 2024, the Group completed Clas I medical
device registration of semen biochemical imunoasay
equipment, thereby further strengthening its reagent
diagnostic capabilities. Trial production of the equipment
has comenced for the Reporting Period, with sales and
promotion activities scheduled to begin in the second half
of this year.
业务回顾
本公司股份（「股份」）于二零一八年十二月
十三日（「上市日期」）于联交所GEM上市
（「上市」），本公司提呈发售新股份（「股份发
售」）。
生物制剂及辅助生育用品和设备分部
本集团继续深耕中国男性不育体外诊断（「体
外诊断」）试剂市场，产品组合增加至31种
生物制剂，包括28种男性不育体外诊断试
剂、2种寄生虫抗体检测试剂及1种EB病毒
检测试剂。
于截至二零二五年六月三十日止六个月（「报
告期间」），该分部收入达人民币12.3百万
元，较截至二零二四年六月三十日止六个月
（「去年同期」）增长3.4%。核心产品男性不
育体外诊断试剂销售额同比增长3.4%至人
民币9.9百万元，占分部总收入的80.6%。
寄生虫系列检测试剂销售亦稳步上升至人民
币1.5百万元，反映市场需求的持续韧性。
于二零二四年底，本集团完成精液生化免疫
分析仪的第二类医疗器械注册，进一步强化
试剂诊断能力。于报告期间已试产了该分析
仪，预计下半年会进行销售及推广活动。
Interim Report 2025 中期报告6
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
健康产品及保健品分部
为发展女性健康市场，本集团透过收购湖南
可悦生物科技有限公司（「可悦生物」）的股权
（「该收购」），取得其在国内女性健康市场丰
富的研发经验、产品线（如「玉坤舒」及「清徽
悦」品牌）及市场渠道。该收购已于二零二五
年六月二十六日完成，其财务业绩将于下半
年贡献本集团。该收购将充分整合本集团的
国际供应链及销售网络与可悦生物的本土能
力，共同拓展海内外女性健康市场，满足女
性消费者日益增长的需求。
未来前景
随著中国于二零二四年十月发报新支持生育
政策（「该政策」），本集团在生物制剂及辅助
生育用品的业务将迎来重要发展机遇。该政
策明确提出强化生育服务支援等措施。本集
团作为专注于男性不育诊断及辅助生育用品
的企业，将受益于该政策驱动的市场需求增
长。通过已完成第二类医疗器械注册的精液
生化免疫分析仪的商用化以及改进现有产
品，本集团将进一步巩固在试剂诊断领域的
领先地位，为医疗机构提供精准、高效的解
决方案，助力国家生育支持政策的落地实
施。
Healthcare Products and Suplements Segment
To develop the women’s health market, our Group
acquired the equity interest (the “Acquisition”) in Hunan
Keyue Biotechnology Company Limited* (“Keyue Bio”),
thereby gaining its extensive research and development
experience, product lines (e.g., “Yukunshu*” and
“Qinghuiyue*” brands), and domestic market chanels
in the female health sector. The Acquisition was
completed on 26 June 2025 and its financial results wil
be contributed to the Group in the second half of this
year. It wil fuly integrate the Group’s global resources
with local capabilities of Keyue Bio to jointly expand
domestic and overseas women’s health markets, meting
the growing health demands of female consumers.
FUTURE PROSPECTS
With the isuance of a new fertility suport policy by
the PRC in October 2024 (the “Policy”), the Group’s
busines in biological reagents and auxiliary reproductive
suplies and equipment is poised to capitalize on
significant development oportunities. The Policy
emphasizes strengthening fertility service suport. As
a company focused on male infertility diagnosis and
auxiliary reproductive suplies and equipment, the
Group wil benefit from the market demand growth
driven by the Policy. Through the comercialization of
its semen biochemical imunoasay equipment, which
has completed registration as a Clas I medical device,
and the improvement of existing products, the Group
wil further consolidate its leading position in the reagent
diagnostics field. This wil enable it to provide precise and
eficient solutions to medical institutions, suporting the
implementation of the national fertility suport policy.
* The English name is for identification purpose
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited7
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
与此同时，本集团透过收购可悦生物股权，
整合其在国内女性健康市场的研发资源与管
道优势。结合本集团通过「Nutronic」品牌积
累的海外供应链及国际网路，双方将协同开
发复盖全生命周期的健康产品，回应该政策
中强化生育服务支援与营造生育友好社会氛
围的目标。未来，本集团将深化技术研发，
拓展分销网路，并探索东南亚等新兴市场，
以创新驱动增长，为股东创造可持续价值。
财务回顾
收益
于报告期间，本集团录得的收益较去年
同期的约人民币11.9百万元增加约人民币
411,000元或约3.4%至约人民币12.3百万
元。收益增加主要由于报告期间，本集团男
性不育体外诊断试剂及寄生虫系列检测试剂
的销售增加。
男性不育体外诊断试剂产品仍为我们的主要
产品，其于报告期间之销售额占本集团生物
制剂及辅助生育用品和设备分部总收益约
80.6%。销售男性不育体外诊断试剂产品于
报告期间之收益约为人民币9.9百万元，较
去年同期的约人民币9.6百万元增加约人民
币327,000元或约3.4%。
Concurently, the Group plans to integrate research
and development resources of Keyue Bio and chanel
advantages in the domestic female health market
through acquisition of its equity. By leveraging the
overseas suply chain and global networks established
through the “Nutronic” brand, the colaboration wil
enable synergistic development of health products that
cover the entire life cycle. This initiative responds to the
Policy’s goals of strengthening fertility service suport and
fostering a fertility-friendly social atmosphere. Loking
ahead, the Group wil depen its technological research
and development, expand its distribution network, and
explore emerging markets such as Southeast Asia to drive
growth through inovation and create sustainable value
for shareholders.
FINANCIAL REVIEW
Revenue
The Group’s revenue increased by aproximately
RMB411,000, or aproximately 3.4%, from aproximately
RMB11.9 milion for the Coresponding Period to
aproximately RMB12.3 milion for the Reporting Period.
The increase in revenue was mainly due to an increase
in the sales of male fertility IVD reagents and parasite
antibody detection reagents for the Reporting Period.
Sales of male fertility IVD reagents products remained to
be our major products which acounted for aproximately
80.6% of our total revenue generated from our sales of
biological reagents and auxiliary reproductive suplies
and equipment segment for the Reporting Period.
Revenue from sales of male fertility IVD reagents products
for the Reporting Period was aproximately RMB9.9
milion, which represented an increase of aproximately
RMB327,000 or aproximately 3.4% from aproximately
RMB9.6 milion for the Coresponding Period.
Interim Report 2025 中期报告8
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
毛利及毛利率
本集团于报告期间录得毛利约人民币8.4百
万元，较去年同期之约人民币8.0百万元增
加约人民币427,000元或约5.3%。
本集团的毛利率由去年同期约67.0%增加至
于报告期间约68.3%。
其他收入及其他亏损及收益
其他收入由去年同期约人民币318,000元减
少约人民币87,000元或约27.4%至于报告期
间约人民币231,000元。该减少乃主要归因
于贷款利息收入减少。
我们于报告期间录得其他亏损约人民币
147,000元，相对我们于去年同期其他收益
约人民币181,000元。有关转变主要由于外
币与人民币的汇率波动，其中大部分为未变
现汇兑差异。
减值亏损
本集团于报告期间录得贸易应收款项减值亏
损（扣除拨回）约人民币381,000元，较去年
同期为约人民币60,000元大幅增加。该大
幅增加主要归因于一些本集团客户偿债能力
的恶化。
此外，本集团于报告期间录得应收贷款及贷
款利息和可收回已支付对价减值亏损回拨约
人民币113,000元，而去年同期并无计提或
回拨同类别的减值准备。此变动主要是于报
告期间应收贷款偿还所致。
Gros Profit and Gros Profit Margin
The Group recorded a gros profit of aproximately
RMB8.4 milion for the Reporting Period, representing an
increase of aproximately RMB427,000, or aproximately
5.3%, from aproximately RMB8.0 milion for the
Coresponding Period.
The Group’s gros profit margin increased from
aproximately 67.0% for the Coresponding Period to
aproximately 68.3% for the Reporting Period.
Other Income and Other Loses and Gains
Other income decreased aproximately RMB87,000 or
aproximately 27.4% from aproximately RMB318,000
for the Coresponding Period to aproximately
RMB231,000 for the Reporting Period. The decrease was
primarily atributable to decrease in loan interest income.
We recorded other loses of aproximately RMB147,000
for the Reporting Period, compared to other gains of
aproximately RMB181,000 for the Coresponding
Period. Such change was mainly atributable to the
fluctuations in foreign exchange rate betwen foreign
curency and RMB, the majority of which was unrealised
foreign exchange diference.
Impairment Loses
The Group recorded impairment loses on trade
receivables (net of reversals) of aproximately
RMB381,000 for the Reporting Period, a significant
increase compared to the RMB60,000 recorded for the
Coresponding Period. This significant increase was
primarily driven by weakened repayment capacities
among some of the Group’s customers.
Aditionaly, the Group recorded a reversal of
impairment loses on loan and loan interest receivables
and refundable consideration paid of aproximately
RMB113,000 for the Reporting Period. No provision
or reversal of impairment los recorded for the same
category for the Coresponding Period. Such change
mainly reflects the repayments of the loan receivables for
the Reporting Period.
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited9
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
开支
销售及分销开支由去年同期约人民币3.9百
万元减少约人民币381,000元或约9.8%至
于报告期间约人民币3.5百万元。该减少乃
主要由于本集团严格控制市场推广费用的开
支。
行政开支由去年同期约人民币4.3百万元大
幅增加约人民币916,000元或约21.5%至于
报告期间约人民币5.2百万元。该大幅增加
乃主要由于就收购事项产生的专业费用开
支、更新医疗器械注册证的注册费用及企业
资源计划系统维护费用。
研发开支由去年同期约人民币2.0万元减少
约人民币159,000元或约8.0%至于报告期间
约人民币1.8百万元。
于报告期间，融资成本为无抵押贷款利息约
人民币45,000元及应用香港财务报告准则
（「香港财务报告准则」）第16号后租赁负债
的利息约人民币23,000元，而去年同期则
约为人民币50,000元。
期内业绩
于报告期间，期内亏损为约人民币2.4百万
元，而去年同期则为约人民币1.8百万元。
该亏损增加约人民币590,000元或约33.2%
主要由于以上提及有关行政开支增加的原
因。
Expenses
Seling and distribution expenses decreased aproximately
RMB381,000 or aproximately 9.8%, from aproximately
RMB3.9 milion for the Coresponding Period to
aproximately RMB3.5 milion for the Reporting Period.
The decrease was primarily atributable to our Group
strictly cost control of the marketing activities.
Administrative expenses significantly increased from
aproximately RMB4.3 milion for the Coresponding
Period to aproximately RMB5.2 milion for the Reporting
Period, which represented an significantly increase of
aproximately RMB916,000 or aproximately 21.5%.
The significantly increase was primarily atributable to
profesional fes incured for the Acquisition; registration
fe for renewing medical device certificates and enterprise
resource planing system maintenance costs.
Research and development expenses decreased from
aproximately RMB2.0 milion for the Coresponding
Period to aproximately RMB1.8 milion for the Reporting
Period, which represented a decrease of aproximately
RMB159,000 or aproximately 8.0%.
During the Reporting Period, finance costs represented
the interest on the unsecured borowings was
aproximately RMB45,000 and the interest on lease
liabilities under aplication of Hong Kong Financial
Reporting Standard (“HKFRS”) 16 was aproximately
RMB23,000 as compared to aproximately RMB50,000
for the Coresponding Period.
Results for the Period
The los for the period was aproximately RMB2.4
milion for the Reporting Period as compared to
aproximately RMB1.8 milion for the Coresponding
Period. The increase in los aproximately RMB590,000
or aproximately 33.2%, was mainly atributable to the
reason mentioned above in relation to the increase of
administrative expenses.
Interim Report 2025 中期报告10
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
于报告期间每股基本亏损为人民币0.47分，
而去年同期则为人民币0.38分。
税项
本集团附属公司适用之中国企业所得税率为
15%（去年同期：15%），而报告期间并无
在香港产生应课税溢利（去年同期：无）。
购股权计划
本公司已根据股东于二零二零年一月十三日
的股东特别大会上通过的一项普通决议案采
纳购股权计划（「购股权计划」）。购股权计划
乃本公司的长期激励计划，旨在奖励其雇
员、董事及其他合资格参与者对本集团作出
贡献，同时协助本集团招聘及挽留高素质雇
员及其他对本集团成长及发展至关重要的合
资格参与者。
于二零二零年四月九日，本公司公布根据购
股权计划向合资格人士授出合共26,008,000
份购股权，惟受限于承受人接纳，行使价为
每股本公司股份0.125港元。于授出日期，
本公司股份的市价为每股份0.125港元。
全部购股权可由承接人接纳日至二零三零年
四月八日行使（包括首尾两日）。各承授人已
于接纳购股权要约时向本公司支付1港元。
有关详情载于本公司日期为二零二零年四月
九日的公告。
Basic los per share for the Reporting Period was
RMB0.47 cent, as compared to RMB0.38 cent for the
Coresponding Period.
Taxation
The PRC enterprise income tax rate aplicable to the
Group’s subsidiaries is 15% (during the Coresponding
Period: 15%), whereas no asesable profit arising from
Hong Kong during the Reporting Period (during the
Coresponding Period: Nil).
SHARE OPTION SCHEME
The Company has adopted the Share Option Scheme
pursuant to an ordinary resolution pased by the
shareholders in the extraordinary general meting on 13
January 2020 (the “Share Option Scheme”). The Share
Option Scheme is a long-term incentive scheme of the
Company to reward its employes, Directors and other
eligible participants for their contributions to the Group
and to asist the Group in its recruitment and retention
of high calibre employes and other eligible participants
who are instrumental to the growth and development of
the Group.
On 9 April 2020, the Company anounced the granting
of an agregate of 26,008,000 share options, subject
to the aceptance by the grantes, at an exercise price
of HK$0.125 per share of the Company to the eligible
persons under the Share Option Scheme. The market
price of the Company’s shares at the date of grant
was HK$0.125 per share. Al of the share options are
exercisable from the date of aceptance by a grante to 8
April 2030 (both days inclusive). Each of the grantes has
paid HK$1 to the Company on aceptance of the ofer
of share option. Details are set out in the Company’s
anouncement dated 9 April 2020.
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited11
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
截至二零二五年六月三十日止期间尚未行使
购股权的变动情况如下：
The movement during the period and the options
outstanding as at 30 June 2025 were as folows:
Number of share options
购股权数目
Category of grantes
As at
1 January
Granted
during the
period
Exercised
during the
period
Forfeited
during the
period
As at
30 June
合资格人士类别
于
二零二五年
一月一日
在此期间
获授
在此期间
行使
在此期间
被没收
于
二零二五年
六月三十日
Executive Directors
执行董事
Mr. Zhang Shuguang4,000,000–4,000,000
张曙光先生
Mr. Zhang Chunguang4,000,000–4,000,000
张春光先生
Mr. He Jiaming4,000,000–4,000,000
何嘉明先生
Other employes7,504,000–7,504,000
其他员工
Total19,504,000–19,504,000
总计
Note: The closing price of the Shares imediately before the
date on which the options were granted is HK$0.125.
The exercise price is HK$0.125. The exercise period
during which the options may be exercised is the
period from the date of aceptance to 8 April 2030
(both days inclusive). The date of grant was 9 April
2020.
No share options had ben granted, exercised or forfeited
during the Reporting Period and the Coresponding
period. As at 30 June 2025, the number of shares in
respect of which options had ben granted and remained
outstanding was 19,504,000 (2024: 19,504,000).
Al the existing share options of the Company are vested
upon granting.
附注： 于所授出之购股权的当日前之股份收市
价为0.125港元。行使价为0.125港元。
可行使购股权之行使期由接纳购股权当
日至二零三零四月八日（首尾两天包括
在内）。授出日期为二零二零四月九日。
于报告期间及去年同期，概无购股权授出、
行使或没收。截至二零二五年六月三十
日，已授出但仍未行使购股权的股份数目
为19,504,000股（二零二四年：19,504,000
股）。
本公司之所有现有购股权乃于授出时归属。
Interim Report 2025 中期报告12
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
于授出日期使用二项式购股权定价模式厘定
之购股权之公平值为每份购股权0.1125港
元，且关键输入数据如下：
计算购股权之公平值时已使用以下假设：
紧接授出日期之前的
收市股价
0.123港元
授出日期之股价0.125港元
行使价0.125港元
预期年期十年
预期波幅103.1%
股息率无
无风险利率0.778%
二项式模式乃用于估计购股权之公平值。购
股权之价值受限于二项式模式的限制及多项
假设，相关假设属主观因素且难以确定。主
观输入值假设如有变动会对公平值估值造成
重大影响。
流动资金、财务资源及资本架构
本集团主要透过经营活动所产生的内部资
金、股权融资及债务融资，为流动资金及资
本需求提供资金。
于二零二五年六月三十日，本集团录得现金
及银行结余总额约为人民币36.7百万元，而
于二零二四年十二月三十一日，本集团之现
金及银行结余总额约为人民币36.5百万元，
分别主要存放于中国主要银行，并分别以人
民币及美元（「美元」）计值。该增加乃主要由
于自持牌放债人的无抵押贷款。
The fair values of share options determined at the date
of grant using the Binomial Option Pricing Model was at
HK$0.1125 per option, with the folowing key inputs:
The folowing asumptions were used to calculate the fair
values of share options:
Closing share price imediately
before date of grant
HK$0.123
Grant date share priceHK$0.125
Exercise priceHK$0.125
Expected life 10 years
Expected volatility103.1%
Dividend yield Nil
Risk-fre interest rate 0.778%
The binomial model has ben used to estimate the fair
value of the share options. The value of the share options
is subject to the limitations of the binomial model and a
number of asumptions which are subjective and dificult
to ascertain. Changes in the subjective input asumptions
could materialy afect the fair value estimate.
LIQUIDITY, FINANCIAL RESOURCES AND
CAPITAL STRUCTURE
Our Group funded the liquidity and capital requirements
primarily through internaly generated funds from
operating activities, equity financing and debt financing.
As at 30 June 2025, our Group recorded total cash
and bank balances of aproximately RMB36.7 milion
compared to aproximately RMB36.5 milion as at 31
December 2024, which were mainly placed with major
banks in the PRC and denominated in RMB and United
States Dolars (“US$”). The increase was mainly due to
the unsecured borowing from the licensed money lender.
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited13
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
于报告期间，本集团与一家持牌放债人签
订贷款协议，总额为港币4百万元。该等贷
款为无抵押、固定年利率为9%，并须于提
取日期后12个月内偿还。于二零二五年六
月三十日，本集团的未动用贷款融资为港
币1.5百万元（二零二四年十二月三十一日：
无）。
于二零二五年六月三十日，无抵押贷款及应
用香港财务报告准则第16号后的租赁负债
分别约人民币2.3百万元及人民币1.3百万元
（二零二四年十二月三十一日：约人民币1.2
百万元）。于二零二五年六月三十日，本集
团的资本负债比率（按无抵押借款及租赁负
债除以权益总额计算）约为7.0%（二零二四
年十二月三十一日：约2.2%）。
本公司股本变动之详情载于未经审核简明综
合财务报表附注19。本集团的资本架构包
括已发行股本、储备及非控股权益。权益总
额于二零二五年六月三十日约为人民币52.1
百万元（二零二四年十二月三十一日：约人
民币54.0百万元）。
雇员及薪酬政策
本集团雇员的薪酬政策乃管理层根据彼等之
特长、资格及能力设立。根据薪酬政策，应
付董事之酬金须由本公司薪酬委员会厘定。
于二零二五年六月三十日，本集团于香港及
中国拥有98名全职雇员（二零二四年十二月
三十一日：91名）开展业务。有关本集团所
产生员工成本（包括董事酬金）之详情，载于
本报告未经审核简明综合财务报表附注之附
注7。
For the Reporting Period, the Group entered into
loan agrements with a licensed money lender in the
agregate amount of HK$4 milion. The loans are
unsecured, fixed interest rate of 9% per anum and
repayable within 12 months after the withdrawal date. As
at 30 June 2025, the Group had unutilised loan facilities
of HK$1.5 milion (31 December 2024: Nil).
As at 30 June 2025, the unsecured borowings and
the lease liabilities under aplication of HKFRS 16
were aproximately of aproximate RMB2.3 milion
and RMB1.3 milion respectively (31 December 2024:
aproximately RMB1.2 milion). The gearing ratio of our
Group calculated based on the unsecured borowings
and the lease liabilities divided by total equity as at 30
June 2025 was aproximately 7.0% (31 December 2024:
aproximately 2.2%).
Details of the movement in the Company’s share capital
are set out in note 19 in the Notes to the unaudited
condensed consolidated financial statements. The capital
structure of the Group comprised of isued share capital,
reserves and non-controling interests. Total equity
amounted to aproximately RMB52.1 milion as at 30
June 2025 (31 December 2024: aproximately RMB54.0
milion).
EMPLOYES AND REMUNERATION POLICIES
The emolument policy for the employe of the Group is
set up by the management on the basis of their merit,
qualifications and competence. Under the emolument
policy, the basis of determining the emolument payable
to Directors is subject to the decision of the remuneration
comite of the Company. As at 30 June 2025,
the Group had 98 ful-time employes (31 December
2024: 91) located in Hong Kong and the PRC for
operation. Details of the staf costs, including Directors’
remuneration, incured by the Group are set out in note
7 in the Notes to the unaudited condensed consolidated
financial statements in this Report.
Interim Report 2025 中期报告14
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
薪酬委员会将考虑董事各自的职责、工作
量、为本集团贡献的时间及本集团的业绩表
现检讨后厘定董事之薪酬及报酬包。
主要风险及不明朗因素
本集团认为营运涉及若干风险及不明朗因
素，其中有一部分乃本集团无法控制。有关
风险因素的详细讨论载于日期为二零一八年
十一月三十日之招股章程「风险因素」一节。
外汇风险
我们营运、资产及负债的功能货币大部分以
人民币计值。因此，除我们的港元、美元及
加元计值银行结余外，我们并无面临任何变
现损失的重大外汇风险。本集团现时并无外
汇对冲政策。本集团并无参与任何衍生工具
协议，且并无承诺任何金融工具以对冲其于
报告期间的外汇风险。管理层将密切监控本
集团的外汇风险，并将于有需要时考虑对冲
重大的外币风险。
库务政策
本集团将继续采用审慎的库务政策管理本集
团的现金结余，并维持稳健的流动资金，以
确保本集团作好准备把握日后的增长机遇。
The remuneration comite wil review and determine
the remuneration and compensation packages of the
Directors after having considered their responsibilities,
workload, time devoted to our Group and the
performance of our Group.
PRINCIPAL RISKS AND UNCERTAINTIES
The Group believed that there were certain risks and
uncertainties involved in the operations, some of which
were beyond the Group’s control. A detailed discusion
of the risk factors was set forth in the section headed “Risk
Factors” in our prospectus dated 30 November 2018.
FOREIGN EXCHANGE EXPOSURE
The functional curencies of our operations, asets and
liabilities were mostly denominated in RMB. Therefore,
we were not exposed to any significant foreign exchange
risk for realised loses, except for our HK$, US$ and CAD$
denominated bank balances. The Group curently did not
have a foreign curency hedging policy. The Group did
not engage in any derivatives agrements and did not
comit to any financial instruments to hedge its foreign
exchange exposure throughout the Reporting Period. The
management wil closely monitor our Group’s foreign
curency exposure and wil consider hedging significant
foreign curency exposure should the ned arises.
TREASURY POLICIES
The Group wil continue to employ a prudent treasury
policy in managing the Group’s cash balances and
maintain strong and healthy liquidity to ensure that the
Group is wel placed to take advantage of future growth
oportunities.
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited15
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
重大收购及出售附属公司及关联公司
于二零二五年四月十六日，本集团订立股权
转让协议以购买可悦生物91%注册资本，
代价为约人民币317,000元。该收购已于二
零二五年六月二十六日完成交割。本集团间
接持有可悦生物91%股权，剩余9%股权由
本公司执行董事张玉静女士直接持有。该收
购的进一步详情，请参阅本公司日期为二零
二四年四月十六日、二零二五年四月三十日
及二零二五年六月二十六日的公告。
除于以上及本报告其他部分所披露者外，本
集团并无作出任何重大收购及出售附属公司
及关联公司。
重大投资持有
于二零二五年六月三十日，本集团并无持有
任何重大投资。
资产抵押
于二零二五年六月三十日，本集团并没有抵
押任何重大资产（二零二四年十二月三十一
日：无）。
资本承担
于二零二五年六月三十日和二零二四年十二
月三十一日，本集团就购买物业、厂房及设
备，没有任何资本承担。
或然负债
于二零二五年六月三十日，本公司概无尚
未偿还公司担保（二零二四年十二月三十一
日：无）。于二零二五年六月三十日，本集
团概无银行融资及并无任何重大或然负债
（二零二四年十二月三十一日：无）。
MATERIAL ACQUISITIONS AND DISPOSALS OF
SUBSIDIARIES AND AFILIATED COMPANIES
On 16 April 2025, our Group entered into the equity
transfer agrement to acquire 91% of registered capital
of Keyue Bio at the consideration of aproximately
RMB317,000. The Acquisition was completed on 26 June
2025, the Group indirectly owns 91% equity interest
in Keyue Bio, and the remaining 9% equity interest is
directly owned by Ms. Zhang Yujing, an executive Director
of the Company. For further details of the Acquisition,
please refer to the anouncements of the Company
dated 16 April 2025, 30 April 2025 and 26 June 2025.
Save as disclosed above and elsewhere in the Report,
the Group did not make any material acquisitions and
disposals of subsidiaries and afiliated companies.
SIGNIFICANT INVESTMENT HELD
As at 30 June 2025, the Group did not have any
significant investment held.
PLEDGE OF ASETS
As at 30 June 2025, the Group did not pledge any asets
of its material for lease liabilities (31 December 2024: Nil).
CAPITAL COMITMENTS
As at 30 June 2025 and 31 December 2024, the Group
did not have any capital comitments in respect of the
acquisition of property, plant and equipment.
CONTINGENT LIABILITIES
As at 30 June 2025, the Company had no outstanding
corporate guarante (31 December 2024: Nil). As at
30 June 2025, the Group had no banking facilities and
did not have any significant contingent liabilities (31
December 2024: Nil).
Interim Report 2025 中期报告16
MANAGEMENT DISCUSION AND ANALYSIS
管理层讨论及分析
有关重大投资或资本资产的日后计划
除本报告其他部分所披露者外，本集团于本
报告日并无其他有关重大投资及资本资产的
计划。
股息
董事不建议派付截至二零二五年六月三十日
止六个月的任何股息（截至二零二四年六月
三十日止六个月：无）。
期后事项
除于本报告其他部分所披露者外，自二零
二五年六月三十日直至本报告日并无发生影
响本公司的重大事件。
FUTURE PLANS FOR MATERIAL INVESTMENTS
OR CAPITAL ASETS
Save as disclosed elsewhere in the Report, the Group
does not have other plans for material investments and
capital asets as at the date of this Report.
DIVIDEND
The Directors do not recomend the payment of any
dividend for the six months ended 30 June 2025 (six
months ended 30 June 2024: Nil).
SUBSEQUENT EVENTS
Save as disclosed elsewhere in the Report, since 30 June
2025 up to the date of this Report no significant events
afecting the Company have taken place.
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited17
OTHER INFORMATION
其他资料
DIRECTORS’ AND CHIEF EXECUTIVE’S
INTERESTS AND SHORT POSITIONS IN SHARES,
UNDERLYING SHARES AND DEBENTURES
As at 30 June 2025, the interests and short positions of
the Directors and chief executive and their asociates
in the Shares, Underlying Shares and debentures of the
Company or any of the asociated corporations (within
the meaning of Part XV of the Securities and Futures
Ordinance (Chapter 571 of the Laws of Hong Kong) (the
“SFO”) which, once the Shares are listed on GEM on the
Stock Exchange, wil have to be notified to the Company
and the Stock Exchange pursuant to Divisions 7 and 8
of Part XV of the SFO (including any interest or short
positions which they are taken or demed to have under
such provision of the SFO) or wil be required, pursuant
to section 352 of the SFO, to be entered in the register
refered to therein, or wil be required, pursuant to the
Rules 5.46 to 5.67 of the GEM Listing Rules relating to
securities transactions by the Directors, to be notified to
the Company and the Stock Exchange pursuant to the
Model Code for Securities Transactions by Directors of
Listed Isuers, wil be as folows:
Long Positions in the Shares
Ordinary shares of HK$0.01 each of the Company
Name of Directors/
chief executive
董事╱最高行政人员姓名
Capacity/Nature of interest
身份╱权益性质
Number of
ordinary
shares held
(1)
所持普通股数目
(1)
Number of share
options held
(3)
所持购股权数目
(3)
Total interest
权益总计
Percentage of
shareholding
(2)
股权百分比
(2)
Mr. Zhang ShuguangBeneficial owner–4,000,0004,000,0000.8%
张曙光先生实益拥有人
Mr. Zhang ChunguangBeneficial owner–4,000,0004,000,0000.8%
张春光先生实益拥有人
Mr. Pon Lai Yin MichaelBeneficial owner4,000,000–4,000,0000.8%
潘礼贤先生实益拥有人
Mr. He JiamingBeneficial owner–4,000,0004,000,0000.8%
何嘉明先生实益拥有人
董事及最高行政人员于股份、相关股
份及债权证的权益及淡仓
于二零二五年六月三十日，董事及最高行政
人员及彼等各自之联系人于本公司或其任
何相联法团（定义见香港法例第571章证券
及期货条例（「证券及期货条例」）第XV部）的
股份、相关股份及债权证中，拥有（一旦股
份于联交所GEM上市后）须根据证券及期货
条例第XV部第7及8分部知会本公司及联交
所的权益及淡仓（包括根据证券及期货条例
有关条文彼等被当作或被视为拥有的任何权
益或淡仓），或根据证券及期货条例第352
条须登记于该条所指的登记册内的权益及淡
仓，或根据有关董事进行证券交易的GEM
上市规则第5.46至5.67条上市发行人董事进
行证券交易之标准守则须知会本公司及联交
所的权益及淡仓如下：
于股份之好仓
本公司每股面值0.01港元之普通股
Interim Report 2025 中期报告18
OTHER INFORMATION
其他资料
附注：
- 。
(2) 此乃基于二零二五年六月三十日的已发行
股份总数500,472,000股计算。
- ╱最高行政人员持有之本公司相关股
份的详情载于「购股权计划」一节。
主要股东及其他人士于股份及相关股
份之权益及淡仓
于二零二五年六月三十日，据董事所知，以
下人士（既非董事亦非本公司最高行政人员）
于股份或相关股份中拥有根据证券及期货条
例第XV部第2及第3分部之条文须向本公司
及联交所披露，或记录于本公司根据证券及
期货条例第336条须存置之登记册内的权益
或淡仓：
Notes:
(1) Al interest stated are long positions.
(2) The calculation is based on the total number of
500,472,000 Shares in isue as at 30 June 2025.
(3) Details of the underlying shares of the Company held by
the Director/chief executives are set out in the section
headed “Share Option Scheme”.
SUBSTANTIAL SHAREHOLDERS’ AND OTHERS
PERSONS’ INTERESTS AND SHORT POSITIONS
IN SHARES AND UNDERLYING SHARES
As at 30 June 2025, so far as is known to the Directors,
the folowing persons (not being a Director or chief
executive of the Company) had interest or short position
in the Shares or underlying Shares which would fel to be
disclosed to the Company and the Stock Exchange under
the provision of Divisions 2 and 3 of Part XV of the SFO
or as recorded in the register required to be kept by the
Company pursuant to Section 336 of the SFO:
Name of Shareholders
Capacity/
Nature of interest
Number of
ordinary
shares held
(1)
Number of share
options heldTotal interest
Percentage of
shareholding
(2)
股东姓名╱名称身份╱权益性质所持普通股数目
(1)
所持购股权数目权益总计股权百分比
(2)
Li King YeungBeneficial owner138,672,000–138,672,00027.7%
李景扬实益拥有人
Yu Chi MauBeneficial owner120,752,000–120,752,00024.1%
余智谋实益拥有人
Notes:
(1) Al interests stated are long positions.
(2) The calculation is based on the total number of
500,472,000 Shares in isue as at 30 June 2025.
附注：
- 。
(2) 此乃基于二零二五年六月三十日的已发行
股份总数500,472,000股计算。
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited19
OTHER INFORMATION
其他资料
董事于合约的权益
除本报告另有披露者外，于报告期间内的任
何时间，本公司或其任何控股公司或附属公
司概无参与订立与本集团业务有关，而本公
司董事及彼等各自关连人士于当中直接或间
接拥有重大权益的重大交易、安排及合约。
董事收购股份或债权证的权利
除本报告另有披露者外，于报告期间的任何
时间及直至本报告日期，董事及本公司最高
行政人员及彼等各自之紧密联系人（定义见
GEM上市规则）概无于本公司及╱或其相联
法团（定义见证券及期货条例）之股份或债权
证中拥有任何权益或获授予或行使可藉收购
本公司及╱或其相联法团股份或债权证而获
取利益之任何权利。
竞争权益
董事确认，于报告期间及直至本报告日期，
概无主要股东或董事或彼等各自之紧密联系
人（定义见GEM上市规则），根据GEM上市
规则第11.04条要求披露于本集团经营业务
以外且直接或间接与本集团业务构成竞争或
可能构成竞争的任何业务中拥有权益。
购买、出售或赎回上市证券
于报告期间，本公司或其任何附属公司概无
购买、出售或赎回本公司任何上市证券。
DIRECTORS’ INTEREST IN CONTRACTS
Save as otherwise disclosed in this Report, no transactions,
arangements and contracts of significance in relation to
the Group’s busines to which the Company, or any of its
holding company or subsidiaries was a party and in which
a Director of the Company and their respective conected
parties had a material interest, whether directly or
indirectly, subsisted at any time for Reporting Period.
DIRECTORS’ RIGHTS TO ACQUIRE SHARES OR
DEBENTURES
Save as otherwise disclosed in this Report, at no time
during the Reporting Period and up to the date of this
Report, have the Directors and the chief executive of the
Company and their respective close asociates (as defined
in the GEM Listing Rules) had any interests in, or had
ben granted, or exercised any rights to acquire benefits
by means of the acquisition of shares in, or debentures
of, the Company and/or its asociated corporations (within
the meaning of SFO).
COMPETING INTERESTS
The Directors confirm that none of the substantial
shareholders or the Directors and their respective
close asociates (as defined in the GEM Listing Rules)
is interested in any busines apart from the busines
operated by our Group which competes or is like to
compete, directly or indirectly, with our Group’s busines
as required to be disclosed pursuant to Rule 11.04 of
GEM Listing Rules during the Reporting Period and up to
the date of this Report.
PURCHASE, SALES OR REDEMPTION OF LISTED
SECURITIES
There were no purchases, sales or redemptions of the
Company’s listed securities by the Company or any of its
subsidiaries during the Reporting Period.
Interim Report 2025 中期报告20
OTHER INFORMATION
其他资料
董事资料变更
除张玉静女士于二零二五年四月十六日获委
任为本公司执行董事、徐永得先生及王亚纯
女士分别于二零二五年一月二十二日及二
零二五年六月三十日获委任为本公司独立
非执行董事，概无须根据GEM上市规则第
17.50A(1)条予以披露之董事资料变动。
企业管治常规
董事会（「董事会」）致力于持守较高的企业管
治标准。
董事会相信，良好的企业管治标准对为本公
司提供框架以保障股东利益、提升企业价
值、制定业务策略及政策，以及提高透明度
及问责性是必不可少的。
本公司已应用GEM上市规则附录C1所载企
业管治守则（「企业管治守则」）载列的原则及
守则条文。
本公司自报告期间及直至本报告日期止期间
（「有关期间」）已采纳及遵守（如适用）企业管
治守则。
董事会将持续监察及检讨本公司的企业管治
常规，以确保遵守企业管治守则。
董事会已检讨本集团的内部监控系统，以确
保建立有效及充分的内部监控系统。董事会
亦召开会议讨论财务、营运及风险管理监
控。
CHANGES IN DIRECTORS INFORMATION
Except for Ms. Zhang Yujing was apointed as an
executive director of the Company and Mr. Tsui Wing
Tak and Ms. Wang Yachun were apointed as an
independent non-executive director of the Company with
efect from 16 April 2025, 22 January 2025 and 30 June
2025 respectively, there is no change in information of
the Directors required to be disclosed pursuant to Rule
17.50A(1) of the GEM Listing Rules.
CORPORATE GOVERNANCE PRACTICES
The Board of the Directors (the “Board“) is comited to
achieving high corporate governance standards.
The Board believes that god corporate governance
standards are esential in providing a framework for the
Company to safeguard the interests of shareholders,
enhance corporate value, formulate its busines
strategies and policies, and enhance its transparency and
acountability.
The Company has aplied the principles and code
provisions as set out in the Corporate Governance Code
(the “CG Code”) contained in Apendix C1 of the GEM
Listing Rules.
The Company adopted and complied with, where
aplicable, the CG Code during the Reporting Period and
up to the date of this Report (the “Relevant Period”).
The Board wil continue to monitor and review the
Company’s corporate governance practices to ensure
compliance with the CG Code.
The Board conducted reviews of the system of internal
controls of the Group to ensure that an efective and
adequate internal control system is in place. The Board
also convened metings to discus financial, operational
and risk management control.
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited21
OTHER INFORMATION
其他资料
进行证券交易的标准守则
本公司已采纳一套有关董事进行证券交易的
操守则作为其本身监管董事证券交易的守
则（「必守标准」），其条款严格程度并不逊于
GEM上市规则第5.48至5.67条所载有关董事
进行证券交易的必守标准（「标准守则」）。经
向全体董事作出特定查询后，全体董事均已
确认彼等于有关期间内已遵守必守标准。
根据标准守则第5.66条，董事亦已要求本公
司的任何雇员、或本公司附属公司的任何董
事或雇员（「有关雇员」），不得利用彼等因在
本公司或附属公司的职务或工作而可能管有
与本公司证券有关的内幕消息，在标准守则
禁止董事买卖证券之期间买卖本公司的证
券。本公司并无获悉有关雇员违反必守标准
的事件。
MODEL CODE FOR SECURITIES TRANSACTIONS
The Company has adopted a code of conduct regarding
securities transactions by the Directors on terms no
les exacting than the required standard of dealings
concerning securities transactions by the Directors as set
out in Rules 5.48 to 5.67 of the GEM Listing Rules (the
“Model Code”) as its own code governing securities
transactions of the Directors (the “Required Standard”).
Having made specific enquiry of al the Directors, al of
them confirm that they have fuly complied with the
Required Standard during the Relevant Period.
Pursuant to Rule 5.66 of the Model Code, the Directors
have also requested any employe of the Company or
director or employe of a subsidiary of the Company (the
“relevant employes”) who, because of his ofice or
employment in the Company or a subsidiary, is likely to
poses inside information in relation to the securities of
the Company, not to deal in securities of the Company
when he would be prohibited from dealing by the
Model Code as if he were a Director. No incident of non-
compliance of the Required Standard by the relevant
employes was noted by the Company.
Interim Report 2025 中期报告22
OTHER INFORMATION
其他资料
DISCLOSURES UNDER RULES 17.22 TO 17.24
OF THE GEM LISTING RULES
On 21 March 2024, Shenzhen Huakang Bio-Medical
Enginering Limited* (“Shenzhen Huakang”) entered
into the Repayment Agrement with Shenzhen Maxson
Technology Development Company Limited* (the
“Vendor”) and Hainan Jinuosai Medical Technology
Company Limited* (the “Target Company”), pursuant
to which, among others, (i) the Target Company shal
repay Shenzhen Huakang the loan of RMB3,800,000 by
six instalments; (i) the Target Company shal repay the
refundable consideration of RMB1,900,000 in the seventh
and eighth instalments; (i) the Target Company shal
repay in the eighth instalment (not later than 31
December 2025) the interests acrued on the loan of
RMB3,800,000 at the rate of 5.75% per anum until al
the outstanding amount of the loan owed by the Target
Company has ben fuly repaid to Shenzhen Huakang;
and (iv) upon the ful repayment of the refundable
consideration, Shenzhen Huakang shal unconditionaly
return 19% equity interest in the Target Company to the
Target Company or its designated representative.
The above loan and refundable consideration were
guaranted by a ded of personal guarante executed by
Mr. Zhang Shuguang in favour of the Group on 21 March
2023. Mr. Zhang Shuguang is a director and substantial
shareholder of the Company.
Details of the above transactions are set out in the
Company’s anouncements dated 6 January 2023, 7
February 2023, 9 February 2023, 30 June 2023, 28 March
2024 and 14 May 2024.
* The English name is for identification purpose
GEM上市规则第17.22至17.24条规定
的披露
于二零二四年三月二十一日，深圳华康生物
医学工程有限公司（「深圳华康」）与深圳市美
丞科技发展有限公司（「卖方」）及海南金诺赛
医疗技术有限公司（「目标公司」）订立了还款
协议，据此其中包括(i)目标公司将通过六期
分期付款方式偿还深圳华康人民币3.8百万
元的贷款；(i)在第七期及第八期分期付款中
偿还人民币1.9百万元的可退回对价款；(i)
目标公司将在第八期分期付款(即不迟于二
零二五年十二月三十一日)中偿还以年利率
5.75%计算人民币3.8百万元贷款的利息，
直到目标公司将所欠贷款的全部未偿还金额
完全偿还给深圳华康；及(iv)当可退回对价
款完全偿还后，深圳华康将无条件将目标公
司19%股权退还目标公司或其指定代表。
以上贷款及可退回对价款已由张曙光先生
（为本公司董事及主要股东）于二零二三年三
月二十一日以本集团为受益人执行了一份个
人担保契据作担保。
有关以上交易的详情载于本公司日期为二零
二三年一月六日、二零二三年二月七日、二
零二三年二月九日、二零二三年六月三十
日、二零二四年三月二十八日及二零二四年
五月十四日的公告。
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited23
OTHER INFORMATION
其他资料
于二零二五年六月三十日，目标公司已按照
还款协议的还款计划向本集团偿还共六期人
民币3.8百万元。根据还款协议目标公司累
计尚欠款项约人民币2.3百万元，占于二零
二五年六月三十日本集团总资产约3.5%。
除上文所披露者外，于二零二五年六月三十
日后及直至本报告日期，本集团概无任何
其他情况会引致GEM上市规则第17.22至
17.24条规定的披露责任。
审核委员会及审阅中期业绩
本公司审核委员会已告成立，并遵照GEM
上市规则第5.28条至第5.33条及企业管治
守则条文第D.3.3及D.3.7条订明其职权范围
（「审核委员会」）。审核委员会由三名独立非
执行董事组成，即徐永得先生（主席）、周国
辉博士及王亚纯女士。
审核委员会的主要职责包括协助董事会审阅
财务资料和申报程序、风险管理和内部监控
系统、内部审核职能的有效性、审核范围和
委任外聘核数师，以及让本公司雇员可对有
关本公司财务申报、内部监控或其他事宜的
潜在不当行为提出关注的安排。
As at 30 June 2025, a total of RMB3.8 milion for the
thre instalments has ben repaid by the Target Company
to the Group in acordance with the repayment schedule
under the Repayment Agrement. The agregate
outstanding amounts to be repaid by the Target Company
under the Repayment Agrement of aproximately
RMB2.3 milion represented aproximately 3.5% of the
total asets of the Group as at 30 June 2025.
Save as disclosed above, subsequent to 30 June 2025
and up to the date of aproval of this Report, the Group
had no other circumstances which would give rise to a
disclosure obligation under rules 17.22 to 17.24 of the
GEM Listing Rules.
AUDIT COMITE AND REVIEW OF INTERIM
RESULTS
The audit comite of the Company has ben established
with its terms of reference in compliance with Rules 5.28
to 5.33 of the GEM Listing Rules, and code provisions
D.3.3 and D.3.7 of the CG Code (“Audit Comite”).
The Audit Comite consists of thre independent non-
executive Directors, namely Mr. Tsui Wing Tak (Chairman),
Dr. Chow Kwok Fai Joseph and Ms. Wang Yachun.
The main duties of the Audit Comite are to asist the
Board in reviewing the financial information and reporting
proces, risk management and internal control systems,
efectivenes of the internal audit function, scope of audit
and apointment of external auditors, and arangements
to enable employes of the Company to raise concerns
about posible improprieties in financial reporting,
internal control or other maters of the Company.
Interim Report 2025 中期报告24
OTHER INFORMATION
其他资料
本报告中的财务信息尚未经过本公司审计师
审阅或审核，但审核委员会成员已审阅于报
告期间集团未经审核简明综合财务业绩，及
认为该等报表的编制符合适用的会计准则、
GEM上市规则的规定及其他适用的法律规
定，并已作出充分披露。
代表董事会
主席兼执行董事
张曙光
香港，二零二五年八月十五日
The financial information in this Report has not ben
reviewed nor audited by the Company’s auditor, but
the Audit Comite has reviewed the unaudited
condensed consolidated financial results of the Group
for the Reporting Period and is of the opinion that
the preparation of such statements complied with the
aplicable acounting standards, the requirements
under the GEM Listing Rules and other aplicable legal
requirements, and that adequate disclosures have ben
made.
On behalf of the Board
Zhang Shuguang
Chairman and Executive Director
Hong Kong, 15 August 2025
| 12,329 |
|---|
| (3,913) |
| 8,416 |
| 231 |
| (147) |
| (3,520) |
| (5,174) |
| (1,839) |
| (381) |
| 113 |
| (68) |
| (2,369) |
| – |
| (2,369) |
| 350 |
| (2,019) |
| RMB cents |
| 人民币仙 |
| (0.47) |
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited25
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF
PROFIT OR LOS AND OTHER COMPREHENSIVE INCOME
未经审核简明综合损益及其他全面收入表
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
The Board of the Directors (the “Board”) is pleased to
anounce the unaudited condensed consolidated results
of the Group for the six months ended 30 June 2025
together with the unaudited comparative figures for the
six months ended 30 June 2024 as folows:
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
NOTESRMB’000RMB’000
附注人民币千元人民币千元
Revenue收入411,918
Cost of sales销售成本(3,929)
Gros profit毛利7,989
Other income其他收入5318
Other loses and gains其他亏损及收益6181
Seling and distribution
expenses
销售及分销开支
(3,901)
Administrative expenses行政开支(4,258)
Research and development
expenses
研发开支
(1,998)
Provision for Impairment loses
on trade receivables, net
贸易应收款项减值
亏损，拨备净额(60)
Reversal of impairment loses
on loan and loan interest
receivables and refundable
consideration paid
应收贷款及贷款利息
及可退回已支付对价
减值亏损回拨
–
Finance costs融资成本(50)
Los before tax除税前亏损7(1,779)
Income tax expense所得税开支8–
Los for the period期内亏损(1,779)
Other comprehensive expense:其他全面开支：
Item that may be reclasified
subsequently to profit or los
其后可能重新分类至
损益的项目
Exchange diference on
consolidation
综合汇兑差额
(236)
Total comprehensive expense
for the period
期内全面开支总额
(2,015)
RMB cents
人民币仙
Los per share atributable to
owners of the Company
本公司拥有人应占
每股亏损9
Basic and diluted基本及摊薄(0.38)
董事会（「董事会」）欣然公布本集团截至二零
二五年六月三十日止六个月的未经审核简明
综合业绩，连同截至二零二四年六月三十日
止六个月的未经审核比较数字如下：
| (2,369) |
|---|
| – |
| (2,369) |
| (2,019) |
| – |
| (2,019) |
Interim Report 2025 中期报告26
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOS
AND OTHER COMPREHENSIVE INCOME
未经审核简明综合损益及其他全面收入表
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
NOTESRMB’000RMB’000
附注人民币千元人民币千元
Los for the period atributable
to:
以下人士应占期内
亏损：
– Owners of the Company– 本公司拥有人(1,779)
– Non-controling interests– 非控股权益–
(1,779)
Total comprehensive expense
for the period atributable to:
以下人士应占期内全面
开支总额：
– Owners of the Company– 本公司拥有人(2,015)
– Non-controling interests– 非控股权益–
(2,015)
| 7,509 |
|---|
| 1,315 |
| 1,119 |
| – |
| 9,943 |
| 3,450 |
| 12,019 |
| 4,446 |
| 169 |
| – |
| 36,725 |
| 56,809 |
| 800 |
| 6,416 |
| 1,040 |
| 862 |
| 2,273 |
| 15 |
| 2,800 |
| 14,206 |
| 42,603 |
| 52,546 |
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited27
UNAUDITED CONDENSED CONSOLIDATED
STATEMENT OF FINANCIAL POSITION
未经审核简明综合财务状况表
At 30 June 2025 于二零二五年六月三十日
30 June 202531 December 2024
二零二五年
六月三十日
二零二四年
十二月三十一日
(unaudited)(audited)
（未经审核）（经审核）
NOTESRMB’000RMB’000
附注人民币千元人民币千元
Non-curent asets非流动资产
Property, plant and
equipment
物业、厂房及设备
117,908
Right-of-use asets使用权资产131,134
Intangible asets无形资产141,457
Interest in asociate于联营公司之权益–
10,499
Curent asets流动资产
Inventories存货2,717
Trade and bils receivables贸易应收款项及应收
票据159,949
Other receivables, deposits
and prepayments
其他应收款项、按金
及预付款项5,549
Tax recoverable可收回税项13
Bank deposit with maturity
over thre months
存款日起三个月以上
到期之银行定期
存款5,000
Bank balances and cash银行结余及现金31,495
54,723
Curent liabilities流动负债
Trade payables贸易应付款项16664
Other payables and acrued
charges
其他应付款项及应计
费用5,709
Contract liabilities合约负债695
Lease liabilities租赁负债1,177
Unsecured borowings无抵押贷款18–
Defered income –
government grants
递延收入－政府补助
Amount due to an asociate应付联营公司款项172,906
11,166
NET CURENT ASETS流动资产净值43,557
TOTAL ASETS LES
CURENT LIABILITIES
资产总值减流动负债
54,056
| 485 |
|---|
| – |
| 485 |
| 52,061 |
| 4,432 |
| 47,597 |
| 52,029 |
| 32 |
| 52,061 |
Interim Report 2025 中期报告28
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
未经审核简明综合财务状况表
At 30 June 2025 于二零二五年六月三十日
30 June 202531 December 2024
二零二五年
六月三十日
二零二四年
十二月三十一日
(unaudited)(audited)
（未经审核）（经审核）
NOTESRMB’000RMB’000
附注人民币千元人民币千元
Non-curent liabilities非流动负债
Lease liabilities租赁负债–
Defered income –
government grants
递延收入－政府补助
NET ASETS资产净值54,048
Capital and reserves资本及储备
Share capital股本194,432
Reserves储备49,616
Equity atributable to owners
of the Company
本公司拥有人应占权益
54,048
Non-controling interests非控股权益–
TOTAL EQUITY权益总额54,048
| 4,432 | 57,000 | 1,943 | 2,665 | (753) | 1,995 | (13,234) | 49,616 | – | 54,048 |
|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | (2,369) | (2,369) | – | (2,369) |
| – | – | – | – | 350 | – | – | 350 | – | 350 |
| – | – | – | – | 350 | – | (2,369) | (2,019) | – | (2,019) |
| – | – | – | – | – | – | – | – | 32 | 32 |
| – | – | – | – | – | – | – | – | 32 | 32 |
| 4,432 | 57,000 | 1,943 | 2,665 | (403) | 1,995 | (15,603) | 47,597 | 32 | 52,061 |
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited29
UNAUDITED CONDENSED CONSOLIDATED
STATEMENT OF CHANGES IN EQUITY
未经审核简明综合权益变动表
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
Atributable to owners of the Company
本公司拥有人应占
Share
capital
Share
premium
Capital
reserve
Statutory
reserve
Translation
reserve
Share
option
reserve
Acumulated
profits/(los)Sub-total
Non-
controling
interestsTotal equity
股本股份溢价资本储备法定储备汇兑储备购股权储备
累计溢利╱
（亏损）小计非控股权益权益总额
RMB’000RMB’000RMB’000RMB’000RMB’000RMB’000RMB’000RMB’000RMB’000RMB’000
人民币千元人民币千元人民币千元人民币千元人民币千元人民币千元人民币千元人民币千元人民币千元人民币千元
At 1 January 2024 (audited)于二零二四年一月一日
（经审核）3,67450,2641,9432,580(446)1,995(8,991)47,345–51,019
Los for the period期内亏损–(1,779)(1,779)–(1,779)
Other comprehensive Income:其他全面收益：
Item that may be reclasified subsequently
to profit or los
其后可能重分类至损益的
项目
Exchange diference on consolidation 综合汇兑差额–(236)–(236)–(236)
Total comprehensive expense for the
period
期内全面开支总额
–(236)–(1,779)(2,015)–(2,015)
Transactions with owners:与拥有人之交易：
Contributions and distributions供款及分派
Isue of new shares upon placing,
net of transaction costs
配售后发行新股，扣除
交易成本7586,735–6,735–7,493
Total transactions with owners与拥有人之交易总额7586,735–6,735–7,493
At 30 June 2024 (unaudited)于二零二四年六月
三十日（未经审核）4,43256,9991,9432,580(682)1,995(10,770)52,065–56,497
At 1 January 2025 (audited)于二零二五年一月一日
（经审核）
Los for the period期内亏损
Other comprehensive Income:其他全面收益：
Item that may be reclasified subsequently
to profit or los
其后可能重分类至损益的
项目
Exchange diference on consolidation 综合汇兑差额
Total comprehensive expense for the
period
期内全面开支总额
Transaction with owners in their
capacity as owners
与拥有人（以其拥有人
身份）的交易
Acquisition of subsidiary 收购子公司
Total transaction with owners in their
capacity as owners
与拥有人（以其拥有人
身份）的交易总额
At 30 June 2025 (unaudited)于二零二五年六月
三十日（未经审核）
| (1,480) |
|---|
| 4,785 |
| 1,575 |
| 4,880 |
| 31,495 |
| 350 |
| 36,725 |
Interim Report 2025 中期报告30
UNAUDITED CONDENSED CONSOLIDATED
STATEMENT OF CASH FLOWS
未经审核简明综合现金流量表
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
RMB’000RMB’000
人民币千元人民币千元
Net cash used in operating
activities
经营活动所用现金净额
(2,819)
Net cash from/(used in) investing
activities
投资活动所得╱（所用）现金
净额(122)
Net cash from financing activities融资活动所得现金净额6,897
Net increase in cash and cash
equivalents
现金及现金等价物增加
净额3,956
Cash and cash equivalents at
begining of the period
年初之现金及现金等价物
32,935
Efect on exchange rate change汇率变动的影响(236)
Cash and cash equivalents at end
of the period, represented by
bank balances and cash
年末之现金及现金等价物，
指银行结余及现金
36,655
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited31
NOTES TO THE UNAUDITED CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
1. GENERAL
Huakang Biomedical Holdings Company Limited was
incorporated in the Cayman Islands as an exempted
company under the laws of the Cayman Islands with
limited liability on 3 August 2017 and its shares are
listed on the GEM of The Stock Exchange of Hong
Kong Limited on 13 December 2018. The adreses
of the registered ofice and principal place of
busines of the Company are set out in the section
headed “Corporate Information” to this Report.
The Group is principaly engaged in research and
development, manufacturing, marketing and sale
of biological reagents and auxiliary reproductive
suplies and equipment in the PRC through its
subsidiary, Shenzhen Huakang, a limited liability
company established in the PRC on 26 June 1992.
The consolidated financial statements are presented
in RMB, which is the same as the functional curency
of the Company and rounded to the nearest
thousand unles otherwise stated.
1. 一般资料
华康生物医学控股有限公司于二零一七
年八月三日根据开曼群岛法律于开曼群
岛注册成立为一间获豁免有限公司，其
股份于二零一八年十二月十三日在香港
联合交易所有限公司GEM上市。本公
司之注册办事处及主要营业地点地址载
于本报告「公司资料」一节。
本集团主要透过其附属公司深圳华康
（于一九二年六月二十六日在中国成
立的有限公司）于中国从事生物制剂及
辅助生育用品和设备的研发、生产、营
销及销售。
综合财务报表以人民币呈例，与本公司
之功能货币相同，且除另有注明外，均
四舍五入至最接近之千位数。
Interim Report 2025 中期报告32
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
2. 呈列基准
未经审核简明综合财务报表乃根据香港
会计师公会（「香港会计师公会」）颁布之
所有适用个别香港财务报告准则（「香港
财务报告准则」）、香港会计准则（「香港
会计准则」）及诠释（下文统称为「香港财
务报告准则」）以及香港公司条例的披露
规定而编制。未经审核简明综合财务报
表亦遵守联交所GEM证券上市规则之
适用披露规定。
编制未经审核简明综合财务报表所采纳
的会计政策与编制本集团截至二零二四
年十二月三十一日止年度的年度综合财
务报表所应用者一致，惟于本集团自二
零二五年一月一日开始之财政期间首次
采用由香港会计师公会颁布的新订及经
修订香港财务报告准则除外。
采纳新订及经修订香港财务报告准则对
本未经审核简明综合财务报表并无重大
财务影响。且本未经审核简明综合财务
报表所应用之会计政策并无重大变动。
未经审核简明综合财务报表乃根据历史
成本基准编制。
未经审核简明综合财务报表尚未由本公
司核数师审核，但已由审核委员会审
阅。
2. BASIS OF PRESENTATION
The unaudited condensed consolidated financial
statements have ben prepared in acordance
with Hong Kong Financial Reporting Standards
(“HKFRSs”) isued by the Hong Kong Institute of
Certified Public Acountants (the “HKICPA”), which
colective term includes al aplicable individual
HKFRSs, Hong Kong Acounting Standards
(“HKASs”) and Interpretations isued by the HKICPA
and the disclosure requirements of the Hong Kong
Companies Ordinance. The unaudited condensed
consolidated financial statements also comply with
the aplicable disclosure requirements of the Rules
Governing the Listing of Securities on GEM of the
Stock Exchange.
The acounting policies adopted in the preparation
of the unaudited condensed consolidated financial
statement are consistent with those aplied in the
preparation of the Group’s anual consolidated
financial statements for the year ended 31 December
2024, except for the adoption of the new and
revised HKFRSs isued by the HKICPA that are
adopted for the first time for the Group financial
period begining on 1 January 2025.
The adoption of the new and revised HKFRSs has had
no significant efect on the unaudited condensed
consolidated financial statements and there have
ben no significant changes to the acounting
policies aplied in the unaudited condensed
consolidated financial statements.
The unaudited condensed consolidated financial
statements have ben prepared under the historical
cost basis.
The unaudited condensed consolidated financial
statements have not ben audited by the Company’s
auditor, but have ben reviewed by the Audit
Comite.
| 9,933 |
|---|
| 1,460 |
| 231 |
| 705 |
| 12,329 |
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited33
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
3. 采用判断及估计
于编制本未经审核简明综合中期财务报
表过程中，管理层于应用本集团会计政
策时作出的重大判断及估计不确定因素
的主要来源与二零二四年度财务报表
所应用者相同。
4. 收益及分部资料
本集团的经营活动归属于研发、生产及
销售(i)生物制剂及辅助生育用品和设备
及(i)健康产品及保健品。
以下为对本集团收益之分析：
(a) 客户合约收益分类
3. USE OF JUDGEMENTS AND ESTIMATES
In preparing this unaudited condensed consolidated
interim financial statements, the significant
judgements made by the management in aplying
the Group’s acounting policies and the key sources
of estimation uncertainty were the same as those
that aplied to 2024 anual financial statements.
4. REVENUE AND SEGMENT INFORMATION
The Group’s operating activities are atributable to
research and development, manufacturing and sales
of (i) biological reagents and auxiliary reproductive
suplies and equipment and (i) healthcare products
and suplements.
The folowing is an analysis of the Group’s revenue:
(a) Disagregation of revenue from contracts
with customers
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
RMB’000RMB’000
人民币千元人民币千元
Sales of biological reagents销售生物制剂
Male fertility IVD reagents男性不育体外
诊断试剂9,606
Parasite antibody
detection reagents
寄生虫系列检测
试剂1,358
Epstein-Bar Virus
antibody detection
reagents
EB病毒检测试剂
Sales of auxiliary reproductive
suplies and equipment
销售辅助生育
用品和设备644
Total总计11,918
Interim Report 2025 中期报告34
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
就资源分配及分部业绩评估而向
本公司执行董事（即主要营运决策
人（「主要营运决策人」）报告的资
料著重于所交付或提供的商品或
服务的类型。厘定本集团可呈报
分部时，概无将主要营运决策人
所识别的经营分部合并计算。
根据本集团内部资料呈报目的，
本公司董事已厘定存在两个可呈
报经营分部，载列如下：
(1) 生物制剂及辅助生育用品和
设备；及
(2) 健康产品及保健品
就评估分类表现及在分类间分配
资源而言，主要营运决策人根据
各分部的经营业绩作出决策。
分部业绩为呈报予主要营运决策
人以供资源分配及评估分部表现
的计量基准，其指各分部赚取的
溢利或产生的亏损，当中并无分
配若干其他收益及亏损、行政开
支、总办公室产生的融资成本、
所得税开支及分占联营公司业绩。
Information reported to the executive directors
of the Company, being identified as the chief
operating decision makers (the “CODM”),
for the purposes of resource alocation and
asesment of segment performance focuses on
types of gods or services delivered or provided.
No operating segments identified by the
CODM have ben agregated in ariving at the
reportable segments of the Group.
Based on the Group’s internal information
reporting purpose, the directors of the Company
have determined that there are two reportable
operating segments which are set out below:
(1) Biological reagents and auxiliary
reproductive suplies and equipment; and
(2) Healthcare products and suplements
For the purpose of asesing segment
performance and alocating resources betwen
segments, the CODM makes decisions acording
to the operating results of each segment.
Segment results, which are the measures
reported to the CODM for the purposes of
resources alocation and asesment of segment
performance, represent the profit earned or los
incured by each segment without alocation of
certain other gains and loses, administrative
expenses, finance costs incured by head ofice,
income tax expense and share result of an
asociate.
| 11,918 | – | |||
|---|---|---|---|---|
| 12,329 | – | 12,329 | ||
| 547 | (705) | |||
| 588 | (545) | 43 | ||
| (134) | ||||
| (2,345) | ||||
| 113 | ||||
| (46) | ||||
| (2,369) | ||||
| – | ||||
| (2,369) | ||||
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited35
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
(b) Segment revenue and results
Six months ended 30 June
截至六月三十日止六个月
Biological reagents and
auxiliary reproductive
suplies and equipment
Healthcare products and
suplementsTotal
生物制剂及辅助生育用品
和设备健康产品及保健品总计
二零二五年二零二四年二零二五年二零二四年二零二五年二零二四年
(Unaudited)(Unaudited)(Unaudited)(Unaudited)(Unaudited)(Unaudited)
（未经审核）（未经审核）（未经审核）（未经审核）（未经审核）（未经审核）
RMB’000RMB’000RMB’000RMB’000RMB’000RMB’000
人民币千元人民币千元人民币千元人民币千元人民币千元人民币千元
Segment revenue分部收益11,918
Segment results分部业绩(158)
Unalocated head
ofice and
corporate income
and expenses
未分配
总办公室及
公司收入及
开支
– Other gains and
loses
－其他收益
及亏损122
– Administrative
expenses
－行政开支
(1,743)
– Reversal of
impairment
loses on loan
and loan interest
receivables and
refundable
consideration
paid
－应收贷款
及贷款利
息及可退
回已支付
对价减值
亏损回拨
–
– Finance costs－融资成本–
Los before taxation除税前亏损(1,779)
Income tax expenses所得税开支–
Los for the period期内亏损(1,779)
(b) 分部收益及业绩
| 12,329 |
|---|
| 12,329 |
Interim Report 2025 中期报告36
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
(d) 有关主要客户的资料
截至二零二五年及二零二四年六
月三十日止六个月，并无单独占
本集团总收益10%或以上的客户
（包括受共同控制实体）。
(c) Geographical information
The folowing table sets out information about
the geographical location of the Group’s
revenue from external customers which are
based on the location of gods delivered.
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
RMB’000RMB’000
人民币千元人民币千元
Revenue from external
customers:
外部客户收益：
The PRC中国11,918
11,918
(d) Information about major customers
None of the customers (including entities under
comon control) individualy acounting for
10% or more of the Group’s total revenue
during the six months ended 30 June 2025 and
2024.
(c) 地域资料
下表载列按货品交付的地区划分
之本集团外部客户收益之地域资
料。
| 154 |
|---|
| 48 |
| 29 |
| – |
| 231 |
| (147) |
|---|
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited37
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
5. 其他收入5. OTHER INCOME
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
RMB’000RMB’000
人民币千元人民币千元
Bank interest income银行利息收入81
Government grants政府补助60
Loan interest income贷款利息收入98
Sundry income杂项收入79
6. OTHER LOSES AND GAINS
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
RMB’000RMB’000
人民币千元人民币千元
Foreign exchange (loses)/gains, net汇兑（亏损）╱收益，
净额181
6. 其他亏损及收益
| 23 |
|---|
| 45 |
| 68 |
| 1,286 |
| 4,690 |
| 1,179 |
| 7,155 |
| 374 |
| 332 |
| 3,913 |
| 738 |
| 567 |
| 137 |
| 81 |
Interim Report 2025 中期报告38
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
7. LOS BEFORE TAX
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
RMB’000RMB’000
人民币千元人民币千元
Finance costs融资成本
Finance charges on
lease liabilities
租赁负债的
财务费用50
Interest on unsecured borowings无抵押贷款利息–
Staf costs, including directors’
remuneration
员工成本，
包括董事薪酬
Directors’ emoluments董事薪酬1,025
Other staf costs:其他员工成本：
Salaries, bonus and
other benefits
薪金、花红及
其他福利4,954
Contributions to defined
contribution plans
定额供款计划供款
1,130
7,109
Other items其他项目
Auditor’s remuneration核数师酬金370
Amortisation of intangible asets
(included in cost of sales)
无形资产摊销
（包含在销售
成本）339
Cost of inventories存货成本3,929
Depreciation of property, plant and
equipment
物业、厂房及
设备折旧830
Depreciation of right-of-use asets使用权资产折旧567
Other rental and related expenses其他租赁及有关开支
– Short term lease－短期租赁49
Los on disposal of property, plant
and equipment
出售物业、厂房及
设备亏损–
7. 除税前亏损
| – |
|---|
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited39
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
8. 所得税开支8. INCOME TAX EXPENSE
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
RMB’000RMB’000
人民币千元人民币千元
Curent tax即期税项
PRC Enterprise Income Tax中国企业所得税
– Curent year－本年度–
The Company and the subsidiaries incorporated
in the BVI are tax-exempted. Entity established in
the PRC is subject to PRC Enterprise Income Tax
at a statutory rate of 25%. Since the Group’s PRC
subsidiary, Shenzhen Huakang is recognised as “New
and High Technology Enterprise” and therefore
is entitled to a concesional tax rate of 15%. The
entitlement of this tax benefit is subject to renewal
by respective tax bureau in the PRC every thre years.
The latest aproval for Shenzhen Huakang enjoying
this tax benefit was obtained in November 2023 for
the thre years ending 15 November 2026.
Hong Kong Profits Tax has not ben provided as the
Group had no asesable profit arising from Hong
Kong for the six months ended 30 June 2025 and
2024.
No provision for defered taxation has ben made
in the unaudited condensed consolidated financial
statements as there were no significant temporary
diferences arising during the six months ended 30
June 2025 and 2024 or at the end of each reporting
period.
本公司及于英属处女群岛注册成立的附
属公司均免税。于中国成立之实体须按
中国企业所得税法定税率25%缴纳税
项。由于本集团的中国附属公司深圳华
康获评为「高新技术企业」，因此可享有
15%的优惠税率。该项税务优惠资格
须每三年获相关中国税务局重续。深圳
华康最近获此税务优惠审批之时间为
二零二三年十一月，有效期为截至二零
二六年十一月十五日止三年。
由于本集团于截至二零二五年及二零
二四年六月三十日止六个月并无在香港
产生应课税溢利，故并无就香港利得税
作出拨备。
由于截至二零二五年及二零二四年六月
三十日止六个月或各报告期末并无重大
暂时性差异，因此未经审核简明综合财
务报表并无计提递延税项拨备。
| (2,369 ) |
|---|
| 500,472 |
|---|
Interim Report 2025 中期报告40
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
9. 本公司拥有人应占每股亏损
本公司拥有人应占每股基本亏损的计算
乃基于以下数据：
9. LOS PER SHARE ATRIBUTABLE TO
OWNERS OF THE COMPANY
The calculation of the basic los per share
atributable to the owners of the Company is based
on the folowing data:
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
RMB’000RMB’000
人民币千元人民币千元
Los:亏损：
Los for the period atributable
to the owners of the Company
for the purpose of basic los per
share
计算每股基本
亏损所用本公司
拥有人应占期内
亏损(1,779)
’000’000
千股千股
Number of shares:股份数目：
Weighted average number of
ordinary shares of the Company
in isue for the purpose of basic
los per share
计算每股基本
亏损所用本公司
已发行普通股
加权平均数464,302
Diluted los per share is the same as basic los per
share as the efect of potential ordinary shares is
anti-dilutive during the six months ended 30 June
2025 and 2024.
截至二零二五年及二零二四年六月三十
日止六个月，由于普通股具有潜在反摊
薄效应，故每股摊薄亏损与每股基本亏
损相同。
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited41
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
10. 股息
截至二零二五年及二零二四年六月三十
日止六个月，本公司概无派付或宣派任
何股息，及自报告期末亦无建议派付任
何股息。
- 、厂房及设备
于截至二零二五年六月三十日止六个
月，本集团购买物业、厂房及设备约
人民币404,000（截至二零二四年六月
三十日止六个月：约人民币301,000）。
12. 收购附属公司
于二零二五年六月二十六日，本集团已
完成收购可悦生物（主要从事研发及销
售女性健康产品）的91%股权，代价为
约人民币317,000元。可悦生物之可识
别资产净值于完成收购日期的公平值总
额为约人民币349,000元。收购事项为
本集团拓展海内外女性健康市场之策略
之一部分。
10. DIVIDEND
No dividend was paid or declared by the Company
during the six months ended 30 June 2025 and
2024, nor has any dividend ben proposed since the
end of the Reporting Period.
11. PROPERTY, PLANT AND EQUIPMENT
During the six months ended 30 June 2025 the
Group acquired property, plants and equipment of
aproximately RMB404,000 (six months ended 30
June 2024: aproximately RMB301,000).
12. ACQUISITION OF SUBSIDIARY
On 26 June 2025, The Group had completed to
acquire 91% equity interest in Keyue Bio, which is
principaly engaged in the research and development
and sales of women’s health products, at a
consideration of aproximately RMB317,000. The
agregated fair value of identifiable net aset of
Keyue Bio on the completion date was aproximately
RMB349,000. The Acquisition was made as part
of the Group’s strategy to expand domestic and
overseas women’s health markets.
Interim Report 2025 中期报告42
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
The fair values of the identifiable asets and liabilities
of Keyue Bio as at the date of completion were as
folows:
(unaudited)
（未经审核）
RMB’000
人民币千元
Consideration for acquisition of
a subsidiary
收购一间附属公司之代价
Cash consideration现金代价317
Plus: Non-controling interest (9%)加：非控股权益(9%)32
Les: Net asets acquired减：所收购资产净值(349)
–
An analysis of cash and cash
equivalents included in cash
flows from investing activities
计入投资活动产生之现金流量之现金及现
金等价物分析
Cash and cash equivalent in
subsidiary
acquired
所收购附属公司之现金及现金等价物
Consideration for acquisition setled
in cash
以现金偿付收购事项之代价
(317)
Net cash outflow on acquisition收购事项之现金流出净额(49)
The transaction costs incured by the Group for
the Acquisition had ben expensed and included in
administrative expenses in the unaudited condensed
consolidated statement of profit or los and other
comprehensive income for the six months ended 30
June 2025.
可悦生物之可识别资产及负债于完成收
购日期之公平值载列如下：
本集团就收购事项所产生之交易成本已
于截至二零二五年六月三十日止六个月
之未经审核简明综合损益及其他全面收
入表中支销并计入行政开支。
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited43
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
13. RIGHT-OF-USE ASETS
Factories and
ofice premises
工厂及
办公室物业
RMB’000
人民币千元
Reconciliation of carying
amount
账面值对账
At 31 December 2024 (audited)于二零二四年十二月三十一日（经审核）1,134
Aditions添置–
Acquisition of subsidiary收购子公司748
Depreciation折旧(567)
At 30 June 2025 (unaudited)于二零二五年六月三十日（未经审核）1,315
At 30 June 2025 (unaudited)于二零二五年六月三十日（未经审核）
Cost成本3,394
Acumulated depreciation累计折旧(2,079)
1,315
Certain leases impose a restriction that, unles the
aproval is obtained from the lesor, the right-of-use
aset can only be used by the Group and the Group
is prohibited from seling or pledging the underlying
asets.
13. 使用权资产
若干租赁实施一项限制，除非获得出租
人批准，否则使用权资产仅限由本集团
使用，并且禁止本集团出售或抵押相关
资产。
Interim Report 2025 中期报告44
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
14. 无形资产14. INTANGIBLE ASETS
Development
costs
发展成本
RMB’000
人民币千元
COST成本
At 31 December 2024 (audited)于二零二四年十二月三十一日（经审核）5,203
Aditions添置–
At 30 June 2025 (unaudited)于二零二五年六月三十日（未经审核）5,203
AMORTISATION摊销
At 31 December 2024 (audited)于二零二四年十二月三十一日（经审核）3,746
Provided for the period 期内拨备338
At 30 June 2025 (unaudited)于二零二五年六月三十日（未经审核）4,084
CARYING VALUES账面值
At 30 June 2025 (unaudited)于二零二五年六月三十日（未经审核）1,119
At 31 December 2024 (audited)于二零二四年十二月三十一日（经审核）1,457
Development costs are internaly generated and has
finite useful lives and amortised on a straight-line
basis over 5 years.
发展成本乃于内部产生，具有限可用年
限，并于5年内按直线法摊销。
| 228 |
|---|
| 18,040 |
| (6,249) |
| 12,019 |
| 2,003 |
|---|
| 3,273 |
| 3,283 |
| 3,460 |
| 12,019 |
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited45
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
15. 贸易应收款项及应收票据15. TRADE AND BILS RECEIVABLES
30 June 202531 December 2024
二零二五年
六月三十日
二零二四年
十二月三十一日
(unaudited)(audited)
（未经审核）（经审核）
RMB’000RMB’000
人民币千元人民币千元
Bils receivables应收票据–
Trade receivables from third parties应收第三方之贸易
应收款项15,828
Les: alowance for credit loses减：信贷亏损拨备(5,879)
Total总计9,949
In general, the Group wil request deposits from
the customers before the gods are delivered and
the amount of deposits requested varies amongst
diferent contracts. For certain long-term customers,
the Group wil deliver the gods without requesting
deposits and alow a credit period from 30 to 180
days (31 December 2024: 30 to 180 days) to these
customers and there is no credit period granted to
other customers. The folowing is an aging analysis
of trade and bils receivables (net of alowances
for credit loses) presented based on the dates of
delivery of gods.
30 June 202531 December 2024
二零二五年
六月三十日
二零二四年
十二月三十一日
(unaudited)(audited)
（未经审核）（经审核）
RMB’000RMB’000
人民币千元人民币千元
0–30 days0至30天1,688
31–90 days31至90天2,418
91–180 days91至180天3,057
Over 181 days超过181天2,786
9,949
一般而言，本集团将要求于货品交付前
向客户收取按金，而且所要求按金数额
因不同合约而有所区别。就若干长期客
户而言，本集团将于不要求按金的情
况下向该等客户交付货品，且授予该
等客户30至180天（二零二四年十二月
三十一日：30天至180天）的信贷期，
而并无向其他客户授出信贷期。下列为
按货品交付日期呈列的贸易应收款项及
应收票据（扣除信贷亏损拨备）账龄分
析。
| 126 |
|---|
| 182 |
| 492 |
| 800 |
Interim Report 2025 中期报告46
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
16. 贸易应付款项
通常，本集团会在取得材料前向供应商
预付款项。部份供应商可在无需预付款
的情况下将材料交付予本集团，该等供
应商已授出介乎30天至90天（二零二四
年十二月三十一日：30天至90天）之信
贷期。基于发票日期的贸易应付款项的
账龄分析如下：
16. TRADE PAYABLES
In general, the Group wil make advance payment to
supliers before the materials are received. Some of
the supliers may deliver the materials to the Group
without requesting advance payment and a credit
period ranged from 30 to 90 days (31 December
2024: 30 to 90 days) is granted by these supliers.
The folowing is an aging analysis of trade payables
presented based on the invoice date:
30 June 202531 December 2024
二零二五年
六月三十日
二零二四年
十二月三十一日
(unaudited)(audited)
（未经审核）（经审核）
RMB’000RMB’000
人民币千元人民币千元
0–30 days0至30天30
31–90 days31至90天97
Over 90 days超过90天537
17. AMOUNT DUE TO AN ASOCIATE
The amount due is unsecured, interest fre and
repayable on demand.
18. UNSECURED BOROWINGS
On 25 March 2025, the Group entered into four
term loan agrements with a licensed money lender
in the agregate amount of HK$4 milion at a fixed
interest rate of 9% per anum. The term loans are
unsecured, interest bearing and repayable within 12
months after the withdrawal date.
As at 30 June 2025, the Group had drawn down
unsecured borowings aproximately amounting to
RMB2.3 milion (equivalent to HK$2.5 milion).
17. 应付联营公司款项
有关应付款项为无抵押、免息及须按要
求偿还。
18. 无抵押借款
本集团于二零二五年三月二十五日与一
家持牌放债人签订四份定期贷款协议，
总额为港币4百万元，固定年利率为
9%。该等定期贷款为无抵押、按利率
计息，并须于提取日期后12个月内偿
还。
截至二零二五年六月三十日，本集团
已提取约人民币2.3百万元（相等于港币
2.5百万元）。
| 615 |
|---|
华康生物医学控股有限公司 Huakang Biomedical Holdings Company Limited47
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
19. SHARE CAPITAL
Number of
shareEquivalent to
股份数目相当于
HK$RMB’000
港元人民币千元
Authorised:法定：
At 31 December 2024 (audited)
and 30 June 2025 (unaudited)
于二零二四年
十二月三十一日
（经审核）及二零二五年
六月三十日（未经审核）1,000,000,00010,000,0008,851
Isued and fuly paid
ordinary shares
at HK$0.01 per share:
每股0.01港元之已发行及
缴足普通股：
At 31 December 2024 (audited)于二零二四年
十二月三十一日
（经审核）500,472,0005,004,7204,432
At 30 June 2025 (unaudited)于二零二五年
六月三十日（未经审核）500,472,0005,004,7204,432
20. RELATED PARTY TRANSACTIONS
(a) Related party transactions
Save as disclosed elsewhere in the unaudited
condensed consolidated financial statements,
the Group had entered into folowing
transactions with its related party during the six
months ended 30 June 2025 and 2024:
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
RMB’000RMB’000
人民币千元人民币千元
Lease and utilities expenses
paid to Shenzhen Junxuan
Biological Technology
Co., Ltd* (“Shenzhen
Junxuan”) (Note 1)
已付深圳君轩生物
技术有限公司
（「深圳君轩」）之
租金及公共开支
（附注1）643
* The English name is for identification purpose
19. 股本
20. 关连方交易
(a) 关连方交易
除于未经审核简明综合财务报表
其他地方之披露外，截至二零
二五年及二零二四年六月三十日
止六个月，本集团与其关连方订
立以下交易：
| 1,167 |
|---|
| 119 |
| 1,286 |
Interim Report 2025 中期报告48
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
未经审核简明综合财务报表附注
For the six months ended 30 June 2025 截至二零二五年六月三十日止六个月
Note:
1. Shenzhen Junxuan is a related company
controled by Mr. Zhang Shuguang, an
executive director of the Company.
(b) Compensation of key management
personel
The emoluments of directors as key
management personel of the Group during the
six months ended 30 June 2025 and 2024 were
as folows:
Six months ended 30 June
截至六月三十日止六个月
二零二五年二零二四年
(unaudited)(unaudited)
（未经审核）（未经审核）
RMB’000RMB’000
人民币千元人民币千元
Salaries, bonuses and
other benefits
薪金、花红及
其他福利907
Contributions to defined
contribution plans
界定供款计划供款
1,025
附注：
1. 深圳君轩为本公司执行董事张
曙光先生的关连公司。
(b) 主要管理人员薪酬
董事（作为本集团主要管理人员）
截至二零二五年及二零二四年六
月三十日止六个月之薪酬如下：